RE(ACT) Discovery Institute

The RE(ACT) Discovery Institute is a not-for-profit organization established as the therapeutic discovery arm of the BLACKSWAN Foundation. Located in the Biopôle life sciences campus in Epalinges, Switzerland, the institute aims to facilitate the translation of academic research into clinical applications, particularly for rare diseases.

The RE(ACT) Discovery Institute invests in the development of novel therapeutics for rare diseases. It provides advisory services to academic research groups, facilitates subcontracting for preclinical and early-stage clinical research, and offers educational programs tailored to the scientific community, emphasizing drug efficiency and safety.

The institute offers advisory services, educational programs, and facilitates research and development for novel therapeutics targeting rare diseases.

<p><strong>What are the eligibility criteria for applying to the RE(ACT) Discovery Institute?</strong></p><p>Applicants should be involved in research related to rare diseases, particularly those focusing on therapeutics development. The institute seeks collaborations with academic research groups and organizations dedicated to this field.</p><p><strong>What is the application process for the RE(ACT) Discovery Institute?</strong></p><p>Interested parties should submit a proposal outlining their research objectives and how they align with the institute's mission. Specific guidelines for submission can be found on their website.</p><p><strong>What types of support does the RE(ACT) Discovery Institute provide?</strong></p><p>The institute offers advisory services, facilitates subcontracting for preclinical and early-stage clinical research, and provides educational programs tailored to the scientific community.</p><p><strong>What makes the RE(ACT) Discovery Institute different from other accelerators?</strong></p><p>Unlike traditional accelerators, the RE(ACT) Discovery Institute focuses exclusively on therapeutics for rare diseases, bridging the gap between academic research and clinical applications.</p><p><strong>What metrics does the RE(ACT) Discovery Institute use to measure success?</strong></p><p>Success is measured by the advancement of projects through preclinical and clinical stages, as well as the successful translation of academic research into viable therapeutic options.</p><p><strong>How long does the program last?</strong></p><p>The duration of specific programs may vary, but the institute emphasizes ongoing educational initiatives and project support.</p>